SMARCB1 and neoplasm: To confirm EPS diagnosis, three of five tumor sites (1, 2, and 5) were validated by western blot for INI1 protein, which is absent in 93% of EPS samples (Fig. 3b) [44] as well as in published cell lines [21, 22].